[Publication] Immuno-Oncology in 2020: What We’ve Learned and What Lies Ahead

  June 16, 2020

IO 2020 Whitepaper Thumbnail

With the start of a new decade, the Association of Community Cancer Centers (ACCC) Immuno-Oncology (IO) Institute is continuing its work to advance equitable access to IO therapies, support high-quality care in community oncology programs, and connect the multidisciplinary team with current, optimal approaches to identifying, treating, and managing patients receiving IO therapies. 

As ongoing advances in immunotherapy for cancer continue to move into the community, this newly published white paper explores the most recent ACCC resources to meet the evolving needs of the multidisciplinary care team and describes next steps for supporting optimal delivery of these therapies.

Designed with all of the members of the cancer team in mind, this whitepaper offers a concise view of the ACCC IO Institute's ever-evolving resources hub, recent institute accomplishments, new priorities, and next steps in IO therapy.

In this 2020 publication, you'll find:

  • The ACCC IO Institute's evolving priorities for 2020 and beyond
  • A Tele-Oncology Research Program aimed to broaden telemedicine implementation in IO
  • Resources to support immune-related adverse events identification and treatment approaches
  • Highlights from a Survivorship Care Plans for Patients Receiving Immunotherapy guide, and more.

News & Press